恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

callispheres载药微球经动脉化疗栓塞用于治疗不可切除肝内胆管癌 -ag捕鱼平台

文字: 2020-8-11    浏览次数:469    


abstract

this study aimed to evaluate the efficacy and safety of doxorubicin-loaded drug-eluting beads transarterial chemoembolization (deb-tace)with callispheres microspheres (csm) in treating unresectable intrahepatic cholangiocarcinoma (icc).

本研究旨在评估阿霉素-callispheres载药微球经动脉化疗栓塞(deb-tace)用于治疗不可切除肝内胆管癌(icc)的有效性及安全性。


88 unresectable icc patients who received deb-tace treatment with csm were retrospectively enrolled in this study. information about treatment response, survival and adverse events were collected. the kaplan-meier curve was used to evaluate progression-free survival (pfs) and overall survival (os), and factors affecting os were determined by cox's proportional hazards regression model.

回顾性纳入88例采用callispheres载阿霉素行deb-tace治疗的不可切除icc患者资料。信息收集涵盖治疗反应、生存以及不良事件发生情况。卡普兰-迈耶曲线用于评估患者无进展生存期(pfs)和总生存期(os)。其中,影响os的因素以cox比例风险回归模型进行确定。


tumor response of the whole sample of 88 patients was partial response (pr) in 58 (65.9%) patients, stable disease (sd) in 19 (21.6%) and progressive disease (pd) in 11 (12.5%) at one month after therapy, with no complete responses (cr). the median pfs and os were 3.0 months and 9.0 months respectively. cox's proportional hazards regression analysis disclosed that subsequent treatment was an independent favorable prognostic factor, while cholangiectasis, extensive intrahepatic tumor burden and extrahepatic metastasis were the three prognostic factors associated with poor survival in icc patients. besides, common adverse events included nausea/vomiting, abdominal pain and transient elevation of liver transaminase in patients treated by deb-tace with csm.

治疗后一个月,88例患者的肿瘤反应中,有58例(65.9%)表现为局部反应、19例(21.6%)病情平稳、11例(12.5%)表现为进行性反应,未有全面反应病例。患者pfs和os中值分别为3个月和9个月。cox比例风险回归分析表明,后续治疗是一个独立的有利预后因素,而胆管扩张、大量的肝内肿瘤负荷以及肝外转移是与不可切除icc患者不良生存相关的三大预后因素。此外,采用callispheres载阿霉素行deb-tace治疗的患者中,其常见的不良事件包括恶心/呕吐、腹痛以及肝脏转氨酶短暂升高。


deb-tace with csm is safe and well-tolerated for unresectable icc patients, with a low complication rate and a relative benefit in terms of survival. subsequent treatments including systemic/loco-regional treatments is an independent favorable prognostic factor, but cholangiectasis, extensive intrahepatic tumor burden and extrahepatic metastases are the three prognostic factors associated with poor survival.

采用callispheres载阿霉素行deb-tace用于治疗不可切除icc患者安全且耐受良好,其应用伴随较低的并发症发生率并在患者生存方面具有相对优势。后续治疗包含系统/局部治疗是一个独立的有利预后因素,但胆管扩张、大量的肝内肿瘤负荷以及肝外转移仍是与不可切除icc患者不良生存相关的三大预后因素。


丨本文译者李靖

郑州大学附属肿瘤医院 微创介入科

原文链接:https://mp.weixin.qq.com/s/ra2lwr4t3r8jti9mmk8tdg